Company profile
ARROWHEAD PHARMACEUTICALS, INC.
NASDAQ:ARWRBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Plozasiran Sodium | approved | — | 0 | — |
| BERSACAPAVIR | phase1_2 | — | 13 | completed, terminated, withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (48)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07662096 | phase1 | recruiting | 2026-06-25 | 2027-07-18 | Arrowhead Pharmaceuticals | A First-In-Human Study of ARO-033 in Adult Participants |
| NCT06937203 | phase1_2 | recruiting | 2025-05-09 | 2027-02-01 | Arrowhead Pharmaceuticals | A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus |
| NCT06700538 | phase1_2 | recruiting | 2024-12-04 | 2027-09-17 | Arrowhead Pharmaceuticals | A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus |
| NCT02604199 | phase2 | terminated | 2015-09-01 | 2017-01-01 | Arrowhead Pharmaceuticals | A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection |
| NCT02604212 | phase2 | terminated | 2015-11-01 | 2016-12-01 | Arrowhead Pharmaceuticals | A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 219947 | NDA | ARROWHEAD PHARMACEUTICALS INC | ||||
Loading… | ||||||